Healthcare | September 22, 2025
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Encouraging early detection and breaking the silence around men’s health
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Subscribe To Our Newsletter & Stay Updated
